Prenetics Global Limited·Healthcare

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced a strategic partnership with Superpower, the preventive health platform backed by over $40 million in venture funding. The first-of-its-kind partnership connects clinical-grade supplementation with comprehensive blood diagnostics, enabling an optimized testing loop to provide consumers with measurable proof behind supplement efficacy.

Prenetics Global (NASDAQ: PRE) CEO and co-founder Danny Yeung told investors the company delivered what he described as a "breakout growth story" in 2025, driven by the rapid expansion of its IM8 direct-to-consumer supplements business and a broader strategic shift to focus on that brand. 2025 performance and IM8 ramp Yeung said Prenetics generated approximately $92

BNP PARIBAS ACCELERATES ASSET MANAGEMENT GROWTH WITH PRE-TAX INCOME SET TO DOUBLE BY 2030 PRESS RELEASE Paris, 17 March 2026 BNP Paribas today unveiled its 2030 Strategic Plan for its scaled and integrated Asset Management platform, positioning it as a key contributor to the Group's trajectory toward a 13% Return on Tangible Equity by 2028. Building on the successful acquisition of AXA IM, BNP Paribas Asset Management now operates at scale across Europe, marking a transformational step in its growth.

Prenetics Global Limited (PRE) Q4 2025 Earnings Call Transcript

Small-cap stocks are crushing the market amid a major rotation away from mega tech as market breadth strengthens, boosted by declining interest rates, solid earnings, and a resilient economy. Every member of the Magnificent 7 has underperformed in 2026, with investors increasingly worried about AI capex spending and stretched valuations. Roughly 65% of Russell 2000 companies have topped Q4 earnings expectations, the best beat rate since 2021.

Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced on February 18, 2026 NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the completion of the sale of its 35% equity interest in Insighta to Tencent for total cash consideration of $70 million. The transaction provides a substantial and immediate increase in Prenetics' cash resources, further strengthening the Company's financial position as it sharpens its focus on the global expansion of IM8, its flagship consumer health brand.
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Healthcare
Medical - Diagnostics & Research
285
2021-07-16
0.27